Obesity - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 560
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O5F2BC0D9C1EN
Leaflet:

Download PDF Leaflet

Obesity - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Obesity - Pipeline Review, H2 2015’, provides an overview of the Obesity’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Obesity
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Obesity
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Obesity Overview
Therapeutics Development
Obesity - Therapeutics under Development by Companies
Obesity - Therapeutics under Investigation by Universities/Institutes
Obesity - Pipeline Products Glance
Obesity - Products under Development by Companies
Obesity - Products under Investigation by Universities/Institutes
Obesity - Companies Involved in Therapeutics Development
Obesity - Therapeutics Assessment
Drug Profiles
Obesity - Recent Pipeline Updates
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Obesity, H2 2015
Number of Products under Development for Obesity - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Obesity - Pipeline by Abeome Corporation, H2 2015
Obesity - Pipeline by Advinus Therapeutics Ltd., H2 2015
Obesity - Pipeline by Aegis Therapeutics, LLC, H2 2015
Obesity - Pipeline by Akron Molecules AG, H2 2015
Obesity - Pipeline by Alize Pharma SAS, H2 2015
Obesity - Pipeline by Amabiotics SAS, H2 2015
Obesity - Pipeline by Ambrx, Inc., H2 2015
Obesity - Pipeline by Amgen Inc., H2 2015
Obesity - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Obesity - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Obesity - Pipeline by AstraZeneca Plc, H2 2015
Obesity - Pipeline by Asubio Pharma Co., Ltd., H2 2015
Obesity - Pipeline by AtheroNova Inc., H2 2015
Obesity - Pipeline by Avaxia Biologics, Inc., H2 2015
Obesity - Pipeline by BioLingus AG, H2 2015
Obesity - Pipeline by BioRestorative Therapies, Inc., H2 2015
Obesity - Pipeline by BioTime, Inc., H2 2015
Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Obesity - Pipeline by Braasch Biotech LLC, H2 2015
Obesity - Pipeline by Bristol-Myers Squibb Company, H2 2015
Obesity - Pipeline by Camurus AB, H2 2015
Obesity - Pipeline by Carmot Therapeutics, Inc., H2 2015
Obesity - Pipeline by Chronos Therapeutics Limited, H2 2015
Obesity - Pipeline by CohBar, Inc., H2 2015
Obesity - Pipeline by CoMentis, Inc., H2 2015
Obesity - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Obesity - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015
Obesity - Pipeline by Diabetica Limited, H2 2015
Obesity - Pipeline by DiscoveryBiomed, Inc., H2 2015
Obesity - Pipeline by Eisai Co., Ltd., H2 2015
Obesity - Pipeline by Eli Lilly and Company, H2 2015
Obesity - Pipeline by Esperion Therapeutics, Inc., H2 2015
Obesity - Pipeline by Euroscreen S.A., H2 2015
Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Obesity - Pipeline by FibroGen, Inc., H2 2015
Obesity - Pipeline by Galenea Corp., H2 2015
Obesity - Pipeline by Genfit SA, H2 2015
Obesity - Pipeline by GlaxoSmithKline Plc, H2 2015
Obesity - Pipeline by GTx, Inc., H2 2015
Obesity - Pipeline by Gubra ApS, H2 2015
Obesity - Pipeline by Handok Inc., H2 2015
Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Obesity - Pipeline by Helsinn Healthcare S.A., H2 2015
Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015
Obesity - Pipeline by Insusense Therapeutics ApS, H2 2015
Obesity - Pipeline by Ionis Pharmaceuticals, Inc., H2 2015
Obesity - Pipeline by Jenrin Discovery, Inc., H2 2015
Obesity - Pipeline by Johnson & Johnson, H2 2015
Obesity - Pipeline by Kainos Medicine, Inc., H2 2015
Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Obesity - Pipeline by Lead Discovery Center GmbH, H2 2015
Obesity - Pipeline by LEO Pharma A/S, H2 2015
Obesity - Pipeline by LG Life Science LTD., H2 2015
Obesity - Pipeline by M Pharmaceutical Inc., H2 2015
Obesity - Pipeline by Magnus Life Science, H2 2015
Obesity - Pipeline by MAKScientific, LLC, H2 2015
Obesity - Pipeline by MedImmune, LLC, H2 2015
Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Obesity - Pipeline by Molecular Design International, Inc., H2 2015
Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H2 2015
Obesity - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Obesity - Pipeline by nLife Therapeutics, S.L., H2 2015
Obesity - Pipeline by Nordic Bioscience A/S, H2 2015
Obesity - Pipeline by Novo Nordisk A/S, H2 2015
Obesity - Pipeline by ObeTherapy Biotechnology, H2 2015
Obesity - Pipeline by Omeros Corporation, H2 2015
Obesity - Pipeline by OPKO Health, Inc., H2 2015
Obesity - Pipeline by Orbis Biosciences, Inc., H2 2015
Obesity - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H2 2015
Obesity - Pipeline by Orexigen Therapeutics, Inc., H2 2015
Obesity - Pipeline by Pfizer Inc., H2 2015
Obesity - Pipeline by PharmaIN Corporation, H2 2015
Obesity - Pipeline by PolyNovo Limited, H2 2015
Obesity - Pipeline by Prometheon Pharma, LLC, H2 2015
Obesity - Pipeline by Radius Health, Inc., H2 2015
Obesity - Pipeline by Regulus Therapeutics Inc., H2 2015
Obesity - Pipeline by Reviva Pharmaceuticals Inc., H2 2015
Obesity - Pipeline by Rhythm Pharmaceuticals, Inc., H2 2015
Obesity - Pipeline by Saniona AB, H2 2015
Obesity - Pipeline by Sanofi, H2 2015
Obesity - Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2015
Obesity - Pipeline by Shionogi & Co., Ltd., H2 2015
Obesity - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2015
Obesity - Pipeline by Sirona Biochem Corp, H2 2015
Obesity - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Obesity - Pipeline by Suven Life Sciences Ltd., H2 2015
Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Obesity - Pipeline by Toray Industries, Inc., H2 2015
Obesity - Pipeline by Umecrine AB, H2 2015
Obesity - Pipeline by Vicore Pharma AB, H2 2015
Obesity - Pipeline by Viking Therapeutics, Inc., H2 2015
Obesity - Pipeline by Virocan Therapeutics Private Limited, H2 2015
Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2015
Obesity - Pipeline by Xenetic Biosciences plc, H2 2015
Obesity - Pipeline by XL-protein GmbH, H2 2015
Obesity - Pipeline by Zafgen Inc., H2 2015
Obesity - Pipeline by Zealand Pharma A/S, H2 2015
Obesity - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Obesity Therapeutics - Recent Pipeline Updates, H2 2015
Obesity - Dormant Projects, H2 2015
Obesity - Dormant Projects (Contd..1), H2 2015
Obesity - Dormant Projects (Contd..2), H2 2015
Obesity - Dormant Projects (Contd..3), H2 2015
Obesity - Dormant Projects (Contd..4), H2 2015
Obesity - Dormant Projects (Contd..5), H2 2015
Obesity - Dormant Projects (Contd..6), H2 2015
Obesity - Dormant Projects (Contd..7), H2 2015
Obesity - Dormant Projects (Contd..8), H2 2015
Obesity - Dormant Projects (Contd..9), H2 2015
Obesity - Dormant Projects (Contd..10), H2 2015
Obesity - Dormant Projects (Contd..11), H2 2015
Obesity - Dormant Projects (Contd..12), H2 2015
Obesity - Dormant Projects (Contd..13), H2 2015
Obesity - Dormant Projects (Contd..14), H2 2015
Obesity - Dormant Projects (Contd..15), H2 2015
Obesity - Dormant Projects (Contd..16), H2 2015
Obesity - Dormant Projects (Contd..17), H2 2015
Obesity - Dormant Projects (Contd..18), H2 2015
Obesity - Dormant Projects (Contd..19), H2 2015
Obesity - Dormant Projects (Contd..20), H2 2015
Obesity - Discontinued Products, H2 2015
Obesity - Discontinued Products (Contd..1), H2 2015
Obesity - Discontinued Products (Contd..2), H2 2015
Obesity - Discontinued Products (Contd..3), H2 2015
Obesity - Discontinued Products (Contd..4), H2 2015
Obesity - Discontinued Products (Contd..5), H2 2015
Obesity - Discontinued Products (Contd..6), H2 2015

LIST OF FIGURES

Number of Products under Development for Obesity, H2 2015
Number of Products under Development for Obesity - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Abeome Corporation
Advinus Therapeutics Ltd.
Aegis Therapeutics, LLC
Akron Molecules AG
Alize Pharma SAS
Amabiotics SAS
Ambrx, Inc.
Amgen Inc.
Arena Pharmaceuticals, Inc.
Arrien Pharmaceuticals, LLC
AstraZeneca Plc
Asubio Pharma Co., Ltd.
AtheroNova Inc.
Avaxia Biologics, Inc.
BioLingus AG
BioRestorative Therapies, Inc.
BioTime, Inc.
Boehringer Ingelheim GmbH
Braasch Biotech LLC
Bristol-Myers Squibb Company
Camurus AB
Carmot Therapeutics, Inc.
Chronos Therapeutics Limited
CohBar, Inc.
CoMentis, Inc.
Daiichi Sankyo Company, Limited
Deltanoid Pharmaceuticals Inc.
Diabetica Limited
DiscoveryBiomed, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Esperion Therapeutics, Inc.
Euroscreen S.A.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Galenea Corp.
Genfit SA
GlaxoSmithKline Plc
GTx, Inc.
Gubra ApS
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Helsinn Healthcare S.A.
Hyundai Pharmaceutical Co., Ltd.
Insusense Therapeutics ApS
Ionis Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
Kainos Medicine, Inc.
Kissei Pharmaceutical Co., Ltd.
Lead Discovery Center GmbH
LEO Pharma A/S
LG Life Science LTD.
M Pharmaceutical Inc.
Magnus Life Science
MAKScientific, LLC
MedImmune, LLC
Mitsubishi Tanabe Pharma Corporation
Molecular Design International, Inc.
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
nLife Therapeutics, S.L.
Nordic Bioscience A/S
Novo Nordisk A/S
ObeTherapy Biotechnology
Omeros Corporation
OPKO Health, Inc.
Orbis Biosciences, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Orexigen Therapeutics, Inc.
Pfizer Inc.
PharmaIN Corporation
PolyNovo Limited
Prometheon Pharma, LLC
Radius Health, Inc.
Regulus Therapeutics Inc.
Reviva Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc.
Saniona AB
Sanofi
Shanghai Pharmaceutical Co., Ltd.
Shionogi & Co., Ltd.
Sinil Pharmaceutical Co., Ltd
Sirona Biochem Corp
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
Toray Industries, Inc.
Umecrine AB
Vicore Pharma AB
Viking Therapeutics, Inc.
Virocan Therapeutics Private Limited
WhanIn Pharmaceutical Co., Ltd.
Xenetic Biosciences plc
XL-protein GmbH
Zafgen Inc.
Zealand Pharma A/S
Zydus Cadila Healthcare Limited
Skip to top


Obesity - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 107 pages
VIVUS, Inc. - Product Pipeline Review - Q4 2010 US$ 500.00 Dec, 2010 · 69 pages
Athersys, Inc. - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 51 pages

Ask Your Question

Obesity - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: